CD93 is a transmembrane protein that has been found to play important roles in regulating tumor angiogenesis, immune responses and intestinal homeostasis. Recent studies have revealed its therapeutic potential in cancer treatment. As an underexplored target, CD93 represents exciting opportunities for drug development and investment. This article will analyze the latest research findings on CD93 and discuss its prospects as an emerging star in cancer immunotherapy.
CD93 interacts with IGFBP7 to modulate tumor vasculature
A study published in July 2021 showed that the interaction between CD93 and IGFBP7 leads to abnormal tumor vasculature. Blocking this interaction promotes vascular maturation, enhances drug delivery and improves the efficacy of chemotherapy drugs. Additionally, CD93 blockade increases tumor-infiltrating effector T cells and strengthens anti-tumor immunity.
CD93 regulates ILC3 function and intestinal homeostasis
Research from Tsinghua University found that interleukin-17D produced by intestinal epithelial cells can bind to CD93 on ILC3s to regulate their function, thereby maintaining intestinal homeostasis.
CD93 plays a key role in tumor angiogenesis
Previous studies have shown that CD93 regulates β1 integrin signaling activation and fibronectin fibrillogenesis during tumor angiogenesis. Knocking out CD93 in mice leads to reduced β1 integrin activation and lack of fibronectin fibrils in tumor vessels.
CD93 is still in early R&D stages with much potential
Compared to crowded target spaces like PD-1/PD-L1, CD93 remains largely unexploited. Starting early R&D around CD93 could establish a competitive edge. Currently, only a few biotech companies and academic institutions are conducting preclinical research on CD93. More investment and effort are warranted to develop CD93 into a rising star for cancer treatment.
In summary, CD93 represents an emerging cancer immunotherapy target with strong therapeutic potential. Blocking CD93 could synergize with other cancer treatments to achieve better clinical outcomes. More research investment in this underexploited area may lead to differentiated and innovative new drugs.